Repurposing drugs to target nonalcoholic steatohepatitis : = Repurposing drugs to target nonalcoholic steatohepatitis
Nonalcoholic fatty liver disease(NAFLD) is a complex disorder that has evolved in recent years as the leading global cause of chronic liver damage. The main obstacle to better disease management pertains to the lack of approved pharmacological interventions for the treatment of nonalcoholic steatohepatitis(NASH) and NASH-fibrosis-the severe histological forms. Over the past decade,tremendous advances have been made in NAFLD research, resulting in the discovery of disease mechanisms and novel therapeutic targets. Hence, a large number of pharmacological agents are currently being tested for safety and efficacy. These drugs are in the initial pharmacological phases(phase 1 and 2),which involve testing tolerability, therapeutic action, and pharmacological issues.It is thus reasonable to assume that the next generation of NASH drugs will not be available for clinical use for foreseeable future. The expected delay can be mitigated by drug repurposing or repositioning, which essentially relies on identifying and developing new uses for existing drugs. Here, we propose a drug candidate selection method based on the integration of molecular pathways of disease pathogenesis into network analysis tools that use OMICs data as well as multiples sources, including text mining from the medical literature..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019-04-21 2019 |
|---|---|
| Erschienen: |
2019-04-21 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2019 |
|---|---|
| Enthalten in: |
World journal of gastroenterology - (2019), 15 vom: 21. Apr., Seite 1783-1796 Original Letters: Enthalten in (DE-576)276271955 (DE-576)276271955 |
| Reihe: |
China Academic Journals (CAJ), E, 医药卫生科技 = Medicine & Public Health |
|---|
| Sprache: |
Chinesisch |
|---|
| Weiterer Titel: |
Repurposing drugs to target nonalcoholic steatohepatitis |
|---|
| Beteiligte Personen: |
Silvia Sookoian [VerfasserIn] |
|---|
| Links: |
oversea.cnki.net [lizenzpflichtig] |
|---|
| Anmerkungen: |
Author info:Silvia Sookoian;Carlos J Pirola;Department of Clinical and Molecular Hepatology, National Scientific and Technical Research Council (CONICET), University of Buenos Aires, Institute of Medical Research (IDIM);Department of Molecular Genetics and Biology of Complex Diseases, National Scientific and Technical Research Council (CONICET), University of Buenos Aires, Institute of Medical Research (IDIM) |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
CAJ630586004 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | CAJ630586004 | ||
| 003 | DE-627 | ||
| 005 | 20230318163206.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230102s2019 cc |||||o 00| ||chi c | ||
| 035 | |a (DE-627)CAJ630586004 | ||
| 035 | |a (SBB-XA)CAJ_ZXXY201915001 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 044 | |c XB-CN | ||
| 084 | |a ASIEN |q DE-1a |2 fid | ||
| 084 | |a R575 |2 clc | ||
| 100 | 0 | |a Silvia Sookoian |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Repurposing drugs to target nonalcoholic steatohepatitis |b = Repurposing drugs to target nonalcoholic steatohepatitis |
| 246 | 3 | 1 | |a Repurposing drugs to target nonalcoholic steatohepatitis |
| 264 | 1 | |c 2019-04-21 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 490 | 0 | |a China Academic Journals (CAJ) |a E |a 医药卫生科技 = Medicine & Public Health | |
| 500 | |a Author info:Silvia Sookoian;Carlos J Pirola;Department of Clinical and Molecular Hepatology, National Scientific and Technical Research Council (CONICET), University of Buenos Aires, Institute of Medical Research (IDIM);Department of Molecular Genetics and Biology of Complex Diseases, National Scientific and Technical Research Council (CONICET), University of Buenos Aires, Institute of Medical Research (IDIM) | ||
| 520 | |a Nonalcoholic fatty liver disease(NAFLD) is a complex disorder that has evolved in recent years as the leading global cause of chronic liver damage. The main obstacle to better disease management pertains to the lack of approved pharmacological interventions for the treatment of nonalcoholic steatohepatitis(NASH) and NASH-fibrosis-the severe histological forms. Over the past decade,tremendous advances have been made in NAFLD research, resulting in the discovery of disease mechanisms and novel therapeutic targets. Hence, a large number of pharmacological agents are currently being tested for safety and efficacy. These drugs are in the initial pharmacological phases(phase 1 and 2),which involve testing tolerability, therapeutic action, and pharmacological issues.It is thus reasonable to assume that the next generation of NASH drugs will not be available for clinical use for foreseeable future. The expected delay can be mitigated by drug repurposing or repositioning, which essentially relies on identifying and developing new uses for existing drugs. Here, we propose a drug candidate selection method based on the integration of molecular pathways of disease pathogenesis into network analysis tools that use OMICs data as well as multiples sources, including text mining from the medical literature. | ||
| 610 | 2 | 4 | |a Department of Clinical and Molecular Hepatology, National Scientific and Technical Research Council (CONICET), University of Buenos Aires, Institute of Medical Research (IDIM) |
| 610 | 2 | 4 | |a Department of Molecular Genetics and Biology of Complex Diseases, National Scientific and Technical Research Council (CONICET), University of Buenos Aires, Institute of Medical Research (IDIM) |
| 650 | 4 | |a 消化系及腹部疾病 | |
| 650 | 4 | |a 内科学 | |
| 650 | 4 | |a 医药、卫生 | |
| 650 | 4 | |a Digestive System Disease | |
| 650 | 4 | |a 医药卫生科技 | |
| 650 | 4 | |a Medicine & Public Health | |
| 650 | 4 | |a Drug discovery | |
| 650 | 4 | |a Drug repositioning | |
| 650 | 4 | |a Fibrosis | |
| 650 | 4 | |a Genetics | |
| 650 | 4 | |a Treatment | |
| 650 | 4 | |a Systems biology | |
| 700 | 0 | |a Carlos J Pirola |4 oth | |
| 773 | 0 | 8 | |6 880-01 |i Enthalten in |t World journal of gastroenterology |d Beijing : WJG Press, 1995 |g (2019), 15 vom: 21. Apr., Seite 1783-1796 |h Online-Ressource |w (DE-627)CAJ318592460 |w (DE-600)2084831-6 |w (DE-576)276271955 |x 2219-2840 |7 nnns |
| 773 | 1 | 8 | |g year:2019 |g number:15 |g day:21 |g month:04 |g pages:1783-1796 |
| 856 | 4 | 0 | |u http://erf.sbb.spk-berlin.de/han/caj/oversea.cnki.net/kcms/detail/detail.aspx?dbcode=CJFD&filename=ZXXY201915001 |x Verlag |y CrossAsia Link |z Deutschlandweit zugänglich |
| 856 | 4 | 0 | |u https://oversea.cnki.net/kcms/detail/detail.aspx?dbcode=CJFD&filename=ZXXY201915001 |x Verlag |z lizenzpflichtig |
| 880 | 0 | 8 | |6 773-01/Hans |i Enthalten in |h Online-Ressource |w (DE-627)CAJ318592460 |w (DE-600)2084831-6 |w (DE-576)276271955 |x 2219-2840 |7 nnns |
| 912 | |a ZDB-1-CAJ | ||
| 912 | |a GBV_NL_CAJ | ||
| 912 | |a FID-ASIEN | ||
| 912 | |a SSG-OLC-OA3.1 | ||
| 912 | |a SSG-OLC-CAJ | ||
| 936 | u | w | |j 2019 |e 15 |b 21 |c 04 |h 1783-1796 |
| 951 | |a AR | ||
| 952 | |j 2019 |e 15 |b 21 |c 04 |h 1783-1796 | ||
| 980 | |2 11 |1 01 |x 0001 |b 65009106X |c 00 |f 5:FIDXASIA |d --%%-- |e --%%-- |j --%%-- |y k |z 02-01-23 | ||
| 981 | |2 11 |1 01 |x 0001 |r http://erf.sbb.spk-berlin.de/han/caj/oversea.cnki.net/kcms/detail/detail.aspx?dbcode=CJFD&filename=ZXXY201915001 | ||